INmune Bio, Inc.
INMB
$7.28
-$0.04-0.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.63% | -41.22% | -49.92% | -68.68% | -44.15% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -86.67% | -72.22% | -58.62% | -49.25% | -33.82% |
| Total Other Non-Cash Items | -6.49% | -9.00% | 26.14% | 2.42% | 5.09% |
| Change in Net Operating Assets | -215.41% | 43.17% | -136.56% | -51.66% | 279.45% |
| Cash from Operations | -223.82% | -63.84% | -148.46% | -555.21% | 40.28% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | -- | -- | -- |
| Issuance of Common Stock | -- | 1,486.06% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16.88% | 667.65% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 820.31% | -1,304.35% | -1,000.00% | 1,544.44% | -114.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -111.74% | 141.30% | 259.44% | -756.17% | -13.58% |